Drug Profile
Adipose stem cell therapy - Anterogen
Alternative Names: Allogeneic mesenchymal stem cells - Anterogen; Adipocell (Anterogen); AdipoPlus; Adipose-derived stem cells; ALLO-ASC; ALLO-ASC-DFU; ALLO-ASC-EB; ALLO-ASC-OA; ALLO-ASC-SHEET; ALLO-ASC-TI; Allogeneic adipose stem cells; ANTG-ASC; Autologous adipose stem cells; Cupistem; QueencellLatest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Anterogen
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Rectal fistula; Scars; Subcutaneous fat disorders
- Phase III Crohn's disease; Diabetic foot ulcer
- Phase II Epidermolysis bullosa
- Phase I/II Tendon injuries
- No development reported Burns; Chronic wounds; IgA nephropathy; Osteoarthritis
Most Recent Events
- 04 Sep 2023 Adipose stem cell therapy is still in phase I/II trials for Epidemolysis bullosa in South Korea (Parenteral, Injection)
- 01 May 2023 Phase-II clinical trials in Epidermolysis bullosa (In adolescents, In adults, In children) in USA (Parenteral) (NCT05157958)
- 30 Apr 2023 Anterogen completes a phase I/II trial in Epidermolysis bullosa in South Korea (Parenteral, Injection) (NCT02579369)